Search for a trial

Short- and long-term effects of oxytocin on empathy in autistic male adults.

Our study aims at investigating whether male adults with ASD differ from healthy male adults in their neurophysiological responses to positive and negative empathy-evoking pictures when taking oxytocin intranasally once. To this end we will compare…

Brain activation during sentence processing in Parkinson's disease: an event related fMRI-study.

The primary goal of this study is to understand the sentence comprehension difficulties in Dutch speaking PD patients. Secondly, we developed the two experiments to test the hypothesis that the BG are involved and play a particular role in syntactic…

Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder.
A 6-month randomised, double-blind, placebo controlled multicentre parallel group study to evaluate efficacy and safety of bumetanide 0.5mg twice a day followed by an open label active 6-month treatment period with bumetanide (0.5mg twice a day) and a 6 weeks discontinuation period after treatment stop.

The primary objective is to demonstrate the superiority of bumetanide (0.5mg BID) oral liquid formulation compared to placebo in the improvement of ASD core symptoms after 6 months of treatment in ASD children and adolescents aged from 7 to less…

A Randomized, investigator/subject blind, adaptive, single and multiple ascending dose, placebo-controlled study to investigate safety, tolerability , pharmacokinetics, pharmacodynamics, food effect and taste of RO7017773 following oral administration in healthy participants.

Part 1, 2 and 3;To assess the safety and tolerability of single and multiple ascending doses of RO7017773 in healthy participants.To investigate the PK of RO7017773 in plasma and urine.To investigate the PD effects of RO7017773 treatment on specific…

SCOPE for improvement of direct care in early childhood: A Social COmmunication Programme supported by E-health for early identification and intervention of social communication problems possibly associated with autism in primary care

Primary Objective:The main objective of this study is to investigate the effectiveness of BEAR (a parent training combining e-learning and home visits) compared to care-as-usual (CAU) in young children (12-30 months) who are at risk of developing…

Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder.
A 6-month randomised, double-blind, placebo controlled multicentre parallel group study to evaluate efficacy and safety of bumetanide 0.5mg twice a day followed by an open label active 6-month treatment period with bumetanide (0.5mg twice a day) and a 6 weeks discontinuation period after treatment stop.

The primary objective is to demonstrate the superiority of bumetanide (0.5mg BID) oral liquid formulation compared to placebo in the improvement of ASD core symptoms after 6 months of treatment in ASD children aged from 2 to less than 7 years old.